Effect of genetic polymorphism on disposition of calcineurin inhibitors in solid organ transplantation.
10.3969/j.issn.1672-7347.2010.09.021
- Author:
Dingyun LI
1
;
Lijun ZHU
;
Qifa YE
Author Information
1. Engineering and Technology Research Center of Transplantation Medicine of National Health Ministry, Third Xiangya Hospital, Central South University, Changsha, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Calcineurin Inhibitors;
Cyclosporine;
pharmacokinetics;
pharmacology;
Cytochrome P-450 CYP3A;
genetics;
Humans;
Immunosuppressive Agents;
pharmacokinetics;
pharmacology;
Organ Transplantation;
Polymorphism, Genetic;
Tacrolimus;
pharmacokinetics;
pharmacology
- From:
Journal of Central South University(Medical Sciences)
2010;35(9):1018-1022
- CountryChina
- Language:Chinese
-
Abstract:
Calcineurin inhibitors, tacrolimus and cyclosporine, characterized by a narrow therapeutic index and a high variability in pharmacokinetic behaviors, are 2 basic immunosuppressive drugs widely used in solid organ transplantation. Tailoring of immunosuppressive drug therapy to the specific requirements of individual patients to optimize the efficacy and minimize the toxicity remains one of the biggest challenges for doctors in solid organ transplantation. Pharmacogenetic and pharmacogenomic researches, studying the effect of genetic polymorphism encoding drug metabolizing enzymes, drug transporters and pharmacological target molecules on drug disposition and action, hold promise to produce useful clinical tools for individualizing immunosuppressive therapy.
